These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2128759)

  • 1. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse.
    Flandina C; Sanguedolce R; Rausa L; D'Alessandro N
    Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):259-72. PubMed ID: 2128759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
    Alderton P; Gross J; Green MD
    Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
    Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
    Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
    Alderton PM; Gross J; Green MD
    Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).
    Herman EH; Ferrans VJ
    Cancer Res; 1981 Sep; 41(9 Pt 1):3436-40. PubMed ID: 6790165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats.
    Zhang J; Herman EH; Ferrans VJ
    Toxicology; 1994 Sep; 92(1-3):179-92. PubMed ID: 7940559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice.
    van Acker SA; Voest EE; Beems DB; Madhuizen HT; de Jong J; Bast A; van der Vijgh WJ
    Cancer Res; 1993 Oct; 53(19):4603-7. PubMed ID: 8402634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.
    Zhang J; Clark JR; Herman EH; Ferrans VJ
    J Mol Cell Cardiol; 1996 Sep; 28(9):1931-43. PubMed ID: 8899552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.
    Hasinoff BB; Reinders FX; Clark V
    Drug Metab Dispos; 1991; 19(1):74-80. PubMed ID: 1673425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
    Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A
    J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line.
    Wadler S; Green MD; Muggia FM
    Cancer Res; 1986 Mar; 46(3):1176-81. PubMed ID: 3080237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.
    Herman EH; Ferrans VJ
    Cancer Chemother Pharmacol; 1993; 32(6):445-9. PubMed ID: 8258192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
    Hasinoff BB
    Drug Metab Dispos; 1990; 18(3):344-9. PubMed ID: 1974197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
    Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
    Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
    Herman EH; Ferrans VJ; Young RS; Hamlin RL
    Cancer Res; 1988 Dec; 48(23):6918-25. PubMed ID: 3141049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin cardiotoxicity and serum lipid increase is prevented by dextrazoxane (ICRF-187).
    Samelis GF; Stathopoulos GP; Kotsarelis D; Dontas I; Frangia C; Karayannacos PE
    Anticancer Res; 1998; 18(5A):3305-9. PubMed ID: 9858900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological changes in the hearts of CD1 mice following chronic treatment with doxorubicin and lonidamine.
    Sanguedolce R; Flandina C; Cucchiara T; Varvara F; Rausa L
    Res Commun Chem Pathol Pharmacol; 1993 Oct; 82(1):81-9. PubMed ID: 8272575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine.
    Herman EH; Ferrans VJ
    Lab Invest; 1983 Jul; 49(1):69-77. PubMed ID: 6408310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.
    Herman EH; Ferrans VJ; Young RS; Hamlin RL
    Drugs Exp Clin Res; 1988; 14(9):563-70. PubMed ID: 3147886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.